Amgen today presented data on overall survival, a secondary endpoint, from the Phase 2 results of the CodeBreaK 100 clinical study for LUMAKRAS TM in previously treated patients with non-small cell lung cancer during the 2021 American Society of Clinical Oncology Annual Meeting. These data were also simultaneously published in the New England Journal of Medicine . The publication includes mature overall .
/PRNewswire/ Amgen (NASDAQ: AMGN) today presented data on overall survival, a secondary endpoint, from the Phase 2 results of the CodeBreaK 100 clinical.
Nucleix : Establishes Collaborative Research and License Agreement with MD Anderson to Develop Methylation Assays to Assess Lung Cancer Patients
06/03/2021 | 08:10am EDT
Send by mail :
Message :
Agreement to build upon research and technical expertise in characterizing methylation patterns in lung cancer
Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, has entered into a collaborative research and license agreement with The University of Texas MD Anderson Cancer Center to evaluate and develop methylation assays focused on lung cancer, using Nucleix’s highly sensitive EpiCheck® platform.
The collaboration will focus initially on evaluating methylation markers believed to be important for the characterization of lung cancer subtypes. Selected markers will be evaluated using EpiCheck – Nucleix’s proprietary platform, which can be run using both PCR and next-generation sequencing technologies, and has shown best-in-class an
USPSTF Expands Criteria for Lung Cancer Screening medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.